The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Evaluation of CD22 modulation as a mechanism of resistance to inotuzumab ozogamicin (InO): Results from central CD22 testing on the Children’s Oncology Group (COG) phase II trial of INO in children and young adults with CD22+ B-acute lymphoblastic leukemia (B-ALL).
 
Nirali N. Shah
No Relationships to Disclose
 
Maureen Megan O'Brien
Research Funding - AbbVie (Inst); Amgen (Inst); Bristol-Myers Squibb (Inst); BTG (Inst); Celgene (Inst); Incyte (Inst); Pfizer (Inst)
 
Constance Yuan
No Relationships to Disclose
 
Lingyun Ji
Consulting or Advisory Role - Millennium
 
Xinxin Xu
No Relationships to Disclose
 
Susan R. Rheingold
Employment - OptiNose (I)
Stock and Other Ownership Interests - OptiNose (I)
Research Funding - Novartis (Inst); Pfizer (Inst)
 
Deepa Bhojwani
No Relationships to Disclose
 
Joanna Yi
No Relationships to Disclose
 
Andrew Harris
No Relationships to Disclose
 
Patrick A. Brown
Consulting or Advisory Role - Jazz Pharmaceuticals; Novartis; SERVIER
 
Michael J. Borowitz
Consulting or Advisory Role - Amgen
Research Funding - Becton Dickinson
Travel, Accommodations, Expenses - Beckman Coulter
 
Meenakshi Devidas
Honoraria - Novartis; PSI
 
Elizabeth A. Raetz
Research Funding - Pfizer (Inst)
Other Relationship - Celgene; Celgene
 
Lia Gore
Employment - Anchiano (I)
Leadership - Anchiano (I); Vedantra (I)
Stock and Other Ownership Interests - Amgen; Anchiano (I); Blueprint Medicines (I); Celgene; Clovis Oncology; Mirati Therapeutics (I); OnKure; Sanofi
Honoraria - Amgen; Roche/Genentech
Consulting or Advisory Role - Amgen; Celgene; Novartis; Roche/Genentech
Patents, Royalties, Other Intellectual Property - Patent held for diagnostic discovery and treatment response methodology tools in the use of MR spectroscopy for leukemia.
Travel, Accommodations, Expenses - Roche/Genentech
 
Mignon L. Loh
Consulting or Advisory Role - MediSix Therapeutics